Skip to content
10-Q

Quarterly Report

Eucrates Biomedical Acquisition Corp.

0001410578-22-001827

← back to feed
Filed
May 23, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 20, 2022 13.46M sh
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$140.08K
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$108.01K
Cash And Equivalents Q1 2022 · Mar 31, 2022 $159.07K
Cash And Equivalents Q1 2022 · Dec 31, 2021 $49.16K
Cash And Equivalents restated Q1 2022 · Mar 31, 2021 $443.25K
Cash And Equivalents restated Q1 2022 · Dec 31, 2020 $551.26K
Stockholders Equity Q1 2022 · Mar 31, 2022 −$4.16M
Stockholders Equity Q1 2022 · Dec 31, 2021 −$5.49M
Stockholders Equity restated Q1 2022 · Mar 31, 2021 −$7.32M
Stockholders Equity restated Q1 2022 · Dec 31, 2020 −$9.31M
Current Liabilities Q1 2022 · Mar 31, 2022 $197.19K
Current Liabilities Q1 2022 · Dec 31, 2021 $38.46K
Total Liabilities Q1 2022 · Mar 31, 2022 $4.55M
Total Liabilities Q1 2022 · Dec 31, 2021 $5.8M
Current Assets Q1 2022 · Mar 31, 2022 $356.15K
Current Assets Q1 2022 · Dec 31, 2021 $264.16K
Total Assets Q1 2022 · Mar 31, 2022 $105.18M
Total Assets Q1 2022 · Dec 31, 2021 $105.11M
Net Income Q1 2022 · Mar 31, 2022 $1.32M
Net Income Q1 2022 · Mar 31, 2021 $1.99M
Operating Income Q1 2022 · Mar 31, 2022 −$131.04K
Operating Income Q1 2022 · Mar 31, 2021 −$125.35K